ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/NSW/2086-Frenchs-Forest-Northern-Beaches-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
8
trial(s) found.
NCT07554339
Curative
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015) (
1084-015
)
KRAS G12C inhibitor,OFF-state inhibitor
anti-PD-L1 monoclonal antibody
placebo
Non-small cell lung cancer
NSW
2086 - Frenchs Forest - Northern Beaches Hospital
NCT07431827
Curative
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Adjuvant Placebo Plus MK-3475A in Participants With Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer Following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (
KANDLELIT-013
)
KRAS G12C inhibitor,OFF-state inhibitor
anti-PD-1 monoclonal antibody
placebo
Non-small cell lung cancer
NSW
2086 - Frenchs Forest - Northern Beaches Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NCT07414836
Advanced
Phase 1
Recruiting
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients With Selected Advanced Solid Tumors (
BG-C0979-101
)
anti-ADAM9 antibody-drug conjugate
Solid tumour
NSW
2086 - Frenchs Forest - Northern Beaches Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT07365319
Advanced
Phase 2 / Phase 3
Recruiting
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (
TeLuRide-008
).
TLR7/TLR8 agonist
anti-PD-1 monoclonal antibody
placebo
Non-small cell lung cancer
Squamous non-small-cell lung cancer
NSW
2086 - Frenchs Forest - Northern Beaches Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3199 - Frankston - PASO Medical
NCT07190248
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007) (
1084-007
)
KRAS G12C inhibitor,OFF-state inhibitor
anti-PD-1 monoclonal antibody
antimetabolite
platinum-based antineoplastic agent
Non-small cell lung cancer
NSW
2086 - Frenchs Forest - Northern Beaches Hospital
2560 - Campbelltown - GenesisCare Campbelltown
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4032 - Chermside - The Prince Charles Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT07011719
Advanced
Phase 3
Recruiting
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma (
PEAK-1
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
HIF2a inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
placebo
Clear cell renal cell carcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2086 - Frenchs Forest - Northern Beaches Hospital
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4032 - Chermside - Icon Cancer Care Chermside
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
TAS
7000 - Hobart - ICON Cancer Care Hobart
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3010 - Rotorua - Rotorua Hospital
NZ.3210 - Hamilton - Waikato Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06596473
Advanced
Phase 1
Recruiting
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients With Selected Advanced Solid Tumors (
BG-C477-101
)
anti-CEACAM5 antibody-drug conjugate
Solid tumour
NSW
2086 - Frenchs Forest - Northern Beaches Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Cancer Research SA
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06065748
Curative
Phase 3
Recruiting
A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy (
CO44657
)
selective estrogen receptor degrader
ER-positive HER2-negative breast cancer
NSW
2060 - North Sydney - Mater Hospital
2086 - Frenchs Forest - Northern Beaches Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.0110 - Whangarei - Whangarei Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (8)
Recruitment Country and State
NSW (8)
VIC (7)
QLD (5)
NZ (3)
SA (3)
WA (2)
TAS (1)
Phase
Phase 1 (2)
Phase 2 / Phase 3 (1)
Phase 3 (5)
Trial Type
Advanced (5)
Curative (3)
Cancer Therapy Class
PD-1/PD-L1
75%
PD-1
63%
KRAS
38%
PD-L1
13%
TLR7/TLR8
13%
AXL
13%
HIF2a
13%
KIT
13%
MET
13%
RET
13%
ROS1
13%
VEGFR
13%
VEGFR2
13%
CEACAM5
13%
CDK4
13%
CDK6
13%
ER
13%
LHRH
13%
oestrogen axis
13%
Facility
2086 - Frenchs Forest - Northern Beaches Hospital (8)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (4)
3199 - Frankston - Peninsula Health Frankston Hospital (3)
3021 - St Albans - Western Health - Sunshine Hospital (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
2170 - Liverpool - Liverpool Hospital (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3199 - Frankston - PASO Medical (1)
2560 - Campbelltown - GenesisCare Campbelltown (1)
4032 - Chermside - The Prince Charles Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2109 - North Ryde - Macquarie University Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
4032 - Chermside - Icon Cancer Care Chermside (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
NZ.3010 - Rotorua - Rotorua Hospital (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
3004 - Melbourne, Southbank - Alfred Health (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
5000 - Adelaide - Cancer Research SA (1)
6009 - Nedlands - One Clinical Research (1)
2060 - North Sydney - Mater Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
NZ.0110 - Whangarei - Whangarei Hospital (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
Cancer Type
Cancer
Solid tumour
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Squamous non-small-cell lung cancer
Clear cell renal cell carcinoma
Kidney cancer
Urogenital cancer
Breast adenocarcinoma
Breast cancer
ER-positive HER2-negative breast cancer
ER-positive breast cancer
HER2-negative breast cancer
HR-positive breast cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy